Add BrightSurf on Google Email

ATP-binding cassette transporter defects and their roles in hepatic diseases

ABCA–ABCG transporters play a crucial role in biliary secretion, with mutations leading to various hepatobiliary disorders. Next-generation genetic testing enables tailored management, while emerging therapies hold promise for cholestatic diseases. Genetic counseling is recommended for family planning and risk assessment.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateJan 28, 2026

Fecal microbiome and bile acid profiles differ in preterm infants with parenteral nutrition-associated cholestasis

This study found differences in fecal microbiome and bile acid content between preterm infants with parenteral nutrition-associated cholestasis (PNAC) and those without PNAC. PNAC development was associated with higher abundance of Proteobacteria, Fusobacteriota, and lower Bacteroidota in cholestatic infants.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateJan 24, 2026

Laparoscopic surgery significantly reduces blood loss and improves jaundice recovery for severe newborn liver disease

A new study by Nagoya University researchers found that laparoscopic surgery significantly reduces blood loss and improves jaundice recovery compared to traditional open surgery for treating biliary atresia. The study analyzed data from 356 children who had surgery at two months old, tracking their outcomes for an average of 13 years.

SourceNagoya University·JournalHepatoBiliary Surgery and Nutrition·TypeObservational study·DateNov 25, 2025

Bile duct injury rates higher from robotic assisted cholecystectomy

A recent study published in JAMA Network Open found that robotic cholecystectomy is associated with a higher risk of bile duct injury compared to the conventional laparoscopic approach. The study, led by Dr. Cody Mullens, analyzed Medicare data and found that bile duct injuries were approximately three times more common in robotic chol...

SourceMichigan Medicine - University of Michigan·JournalJAMA Network Open·TypeData/statistical analysis·DateApr 29, 2025

Hepatic biliary adenofibroma: Histological characteristics, diagnostic challenges, and its role as a precursor to intrahepatic cholangiocarcinoma

Hepatic biliary adenofibroma (BAF) is a rare, benign tumor with histological characteristics distinct from other biliary tumors. Emerging case reports suggest potential for malignant transformation and overlap with intrahepatic cholangiocarcinoma (iCCA), highlighting diagnostic challenges and need for further research.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateFeb 28, 2025

Ursodeoxycholic acid for the management of drug-induced liver injury: Role of hepatoprotective and anti-cholestatic mechanisms

Ursodeoxycholic acid (UDCA) exhibits a broad range of hepatoprotective mechanisms, including antioxidant, anti-inflammatory, and anti-apoptotic properties, which may benefit various types of drug-induced liver injury. In hepatocellular DILI, UDCA reduces inflammation, alleviates ER stress, and protects against mitochondrial damage. In ...

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateFeb 28, 2025

Subnormal serum liver enzyme levels

Subnormal serum liver enzyme levels can result from deficiencies in pyridoxal 5'-phosphate (vitamin B6), as well as conditions such as chronic kidney disease. Recognizing these patterns is crucial for early diagnosis and management of diseases, allowing for targeted treatments and improved patient outcomes.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateJul 2, 2024

The therapeutic effects of baicalein on the hepatopulmonary syndrome in the rat model of chronic common bile duct ligation

This study explored the preventative role of baicalein in hepatopulmonary syndrome development. Baicalein improved survival rates, reduced angiogenic protein levels, and enhanced glucose homeostasis in HPS rats. It also attenuated pathological angiogenesis in the liver and lungs.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 29, 2024

New precision therapy for bile duct cancer extends patients’ lives

A new personalized treatment for bile duct cancer has shown remarkable results, with patients surviving for up to two years when treated with the drug futibatinib. The Phase II clinical trial found that the drug was more effective at reducing tumor size and producing modest side effects compared to chemotherapy.

SourceUniversity College London·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 18, 2023

Novel approach to treat and prevent Type 2 diabetes: SGH and NUS Medicine study

Researchers found that individuals with CYP8B1 loss-of-function mutations have improved insulin sensitivity and better glucose regulation, reducing the risk of developing Type 2 diabetes. The study suggests a potential new treatment approach using bile acid modulators to target this gene.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalJournal of Clinical Investigation·TypeRandomized controlled/clinical trial·DateNov 17, 2022

New Chinese Medical Journal review elucidates potential contributors to non-alcoholic fatty liver disease

A new Chinese Medical Journal review article elucidates the potential contributors to non-alcoholic fatty liver disease (NAFLD) progression, highlighting the role of bile acid and sphingolipid biology. Researchers summarize current understanding of NAFLD, its progression, and potential therapeutic strategies.

SourceCactus Communications·JournalChinese Medical Journal·TypeSystematic review·DateSep 20, 2022

NUS scientists engineer probiotic to prevent infection of large intestine

Researchers from NUS Medicine developed a probiotic that detects antibiotic-induced microbiome imbalance and regulates bile salt metabolism to prevent Clostridioides difficile infection. The probiotic significantly reduced CDI in laboratory models, demonstrating a 100% survival rate and improved clinical outcomes.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalNature Communications·TypeExperimental study·DateAug 3, 2022

Bacteria in the bile duct may provide a new clue for treating liver disease

Researchers discovered a link between the immune system and microbiome in primary sclerosing cholangitis (PSC), a liver disease associated with inflammatory bowel disease. MAIT cells activated by bile-derived pathogens could play an important role in PSC pathophysiology, offering potential new treatment implications.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateMar 16, 2022

Immune cells in the human biliary system mapped

The study reveals a dominant network of neutrophils and tissue-resident T cells in the bile ducts of patients with primary sclerosing cholangitis (PSC), a severe inflammatory disease. This discovery may pave the way for new treatment strategies against PSC and other biliary disorders.

SourceKarolinska Institutet·JournalScience Translational Medicine·DateJun 23, 2021